All In Biotech

Drug Trial Radar · NCT02674399

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

A Phase 2, Double-Blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Treatment of Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Aug 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

28

Actual

Start

Feb 16, 2016

Primary completion

Mar 12, 2018

Study completion Dec 28, 2018

Sponsor

Lead sponsor
Nature Cell Co. Ltd.Industry
Sponsor type
Industry
Collaborators
KCRN Research, LLC
First posted
Feb 4, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 22 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a double-blind, randomized, controlled study with two arms to evaluate JointStem as a treatment for subjects with osteoarthritis. Following a 2-week screening period, approximately 30 subjects will be randomly assigned into one of the following two arms in a 2:1 ratio (2 JointStem : 1 positive control). After each subject completes 6-month visit (Visit 6) and the data management team confirms all data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.Only subjects who are assigned will be requested to visit the study center for 9-month and 12-month follow-up visits (Visits 7 and 8). To see long-term effects of JointStem, all subjects who complete Visit 6 will be requested to visit the study center at 24-month after the injection.

Conditions

  • Osteoarthritis, Knee

Interventions

  • JointStemDrug

  • Synvisc-OneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem GroupTime frame: Baseline and 6 months
  2. Change From Baseline on Visual Analog Scale (VAS) in JointStem GroupTime frame: Baseline and 6 months
  3. MRI Improvement Evaluation in JointStem GroupTime frame: 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Orthopedic Pain Specialists

    Santa Monica, California

  • Site not named

    Walnut Creek, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.